Systemic Sclerosis (SSc) - Healing Genes

Systemic Sclerosis (SSc)

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis (SSc)

Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Patients With Treatment Resistant Systemic Sclerosis (SSc)

Phase 2


Doctors at the University of Pittsburgh Medical Center seek patients with one of the following types of sclerosis for an investigatory treatment trial to deliver the patient’s own stem cells following chemotherapy:

  • Systemic Sclerosis
  • Diffuse Sclerosis
  • Systemic Interstitial Lung Disease
  • Pulmonary Hypertension

Researchers will withdraw stem cells, sorting out a desired type of stem cells carrying CD34 markers. After a round of radiation and chemotherapy intended to deplete the patient’s immune system, the stem cells will be restored as an autologous (self) transplantation.


  • Be 16 to 70 Years of age
  • Have been diagnosed with Systemic Sclerosis (SSc)
  • Be negative for HIV, Hepatitis B, and Hepatitis C
  • Not be pregnant
  • Meet screening criteria for the state of their disease


  1. Screening before the treatment
  2. Blood apheresis using the CliniMACS system will draw the needed immune cells but return blood cells to the body
  3. A complete course of radiation and chemotherapy will be delivered
  4. The autologous stem cells will be returned to the patient
  5. Close follow up for 36 months


Trials will take place at 3 locations of the University of Pittsburgh Medical Center. Map.


Contact: Paul Szabolcs, MD  |  412-692-6225  |  [email protected]

Contact: Shawna McIntyre, RN  |  412-692-5552  |  [email protected]




Paul Szabolcs


Or go online:


Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader